Endocarditis After Redo TAVR Managed With Medical Treatment and Later TAVR-in-TAVR-in-TAVR

再次经导管主动脉瓣置换术后发生心内膜炎,采用药物治疗,后行经导管主动脉瓣置换术(TAVR-in-TAVR-in-TAVR)

阅读:1

Abstract

BACKGROUND: Infective endocarditis after transcatheter aortic valve replacement (TAVR) is a rare but serious condition, with high morbidity and mortality, often requiring surgery. CASE SUMMARY: An 89-year-old woman with prior TAVRs (Sapien 3 and Evolut Pro) presented with dyspnea and fever. Blood cultures grew Staphylococcus hominis, and imaging confirmed endocarditis with minimal aortic regurgitation. She was deemed inoperable owing to age and comorbidities and was treated with lifelong antibiotics. After 18 months, she developed severe aortic regurgitation and heart failure due to structural valve degeneration (SVD). Active infection was excluded, and TAVR-in-TAVR-in-TAVR using a 20-mm Sapien 3 Ultra was performed successfully. DISCUSSION: This case illustrates the feasibility of prolonged medical management for post-TAVR endocarditis in high-risk patients, with redo TAVR for subsequent SVD. TAKE-HOME MESSAGE: Lifelong antibiotics and redo TAVRs in case of later SVD may be viable in frail patients, avoiding the risks of surgery.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。